Company announcement 03/2023.

Roskilde, April 28. 2023

Apillet has further studied the design factors that governs the release onset of the APIVault encapsulation.

Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the results of studies of the design factors that governs the release onset of its APIVault encapsulation material. The APIVault encapsulation material is produced solely from natural materials with a combination of bacterial cellulose and cellulases.

We are thrilled to share our findings on the design factors of the combo material controlling the release of encapsulated material. We have conducted systematic studies on how these factors affect the release properties and found that the feature of the material is remarkably consistent. The release mechanism is based on a percolation process. This means that we can achieve a low and controlled leakage before percolation and a rapid release after percolation. We are very happy to share this remarkable result that opens new possibilities for applications of the APIVault technology.

Apillet is currently defining additional development work and is actively looking for additional investments or pharma collaborations for the development of APIVault.